Powered by

Gilead Stock Rallied on Covid-19 Drug Hopes. This Is as Good as It Gets, Analyst…

Apr 20, 2020 - Nasdaq

T wo analysts have downgraded the biotech stock from Buy-equivalent ratings after a rally last week. Gilead stock has gained on hopes for its coronavirus drug, now in trial. Two analysts have downgraded the biotech stock from Buy-equivalent ratings after a rally last week. Gilead stock has gained on hopes for its coronavirus drug, now in trial. Gilead Sciences stock climbed 9.7% on Friday after health-care news website STAT reported that the company’s experimental Covid-19 drug remdesivir ap...